AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05007041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® High-Dose Quadrivalent
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study NCT05007041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX®
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study NCT05755386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study NCT05755386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iptacopan
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study NCT05072964 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FARAPULSE Pulsed Field Ablation System
Description: A pulmonary vein isolation will be performed using catheter ablation
Study NCT06349512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT imaging
Description: The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
Study NCT05593536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education
Description: Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
Study NCT04432090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Study NCT04432090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Medication (MBX-2982)
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Study NCT04432090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No medication for this group
Description: This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
Study NCT06124521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ComBaT Glaucoma
Description: ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
Study NCT05157620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-based Exercise (YE)
Description: The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
Study NCT05157620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Lifestyle Program (WLP)
Description: The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
Study NCT05276622 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)
Study NCT05276622 — intervention group
Intervention type: OTHER
Intervention: Qualitative patient-care partner interviews
Description: Semi-structured Interviews: Baseline and again at 3 months.
Study NCT05276622 — intervention group
Intervention type: OTHER
Intervention: Surveys on well-being and function
Description: Care partner's Surveys on well-being and function: Baseline and again at 3 months
Study NCT06042361 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smokefree Implementation Framework and Toolkit
Description: Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities.
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be vaporized using the Mighty Medic
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cannabis
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Alcohol
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.
Study NCT06293040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alcohol
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.
Study NCT06305312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Service Navigation
Description: Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.
Study NCT06305312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard referral to community resources.
Study NCT05663944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.5Mg Tab
Description: Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study NCT05663944 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy
Description: After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
Study NCT05663944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy
Description: After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
Study NCT05663944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.5mg capsule
Description: Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Blood Tests
Description: During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Blood Tests
Description: During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Clinical Examination
Description: A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Clinical Examination
Description: A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Week 1 - 5 Titration Blood Tests
Description: Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Week 1 - 5 Titration Blood Tests
Description: Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Month 2 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Month 2 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Month 2 Blood Tests
Description: During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Month 2 Blood Tests
Description: During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Month 4 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Month 4 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Month 4 Blood Tests
Description: During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Month 4 Blood Tests
Description: During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Month 6 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Month 6 Clinical Examination
Description: A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Month 6 Blood Tests
Description: During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Month 6 Blood Tests
Description: During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study
Study NCT05663944 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy
Description: All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
Study NCT06381817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo-cord HCT
Description: Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit
Study NCT06381817 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haplo-HCT
Description: Hematopoietic cell transplantation will be performed with a haploidentical donor
Study NCT06317064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Aprepitant
Description: All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days.
Study NCT05691348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory appendectomy
Description: Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
Study NCT05691348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional appendectomy
Description: Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
Study NCT06411210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Escalated to 2.4mg or max tolerated dose
Study NCT06411210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.